Skip to content
Arthritis · 24 May 2026

What Are the 11 Criteria for Lupus? A Plain-English Guide to Diagnosis

What are the 11 criteria for lupus?

The 11 criteria for lupus come from the original American College of Rheumatology (ACR) classification system. They are: butterfly rash on the face, discoid (coin-shaped) rash, sun sensitivity, mouth sores, arthritis, serositis (inflammation around the lungs or heart), kidney problems, neurological problems, low blood counts, immune system abnormalities, and a positive ANA blood test.

Traditionally, meeting 4 of these 11 criteria was used to classify a patient as having lupus. That rule was designed for research consistency, not for diagnosing individual patients. The criteria have since been updated twice.

In practice today, rheumatologists use all three major classification systems together: the original 1997 ACR criteria (11 items), the 2012 SLICC criteria (17 items), and the 2019 EULAR/ACR criteria (a weighted point-based system). Diagnosis is a clinical judgment call, not a checklist exercise.

What Are the 11 Criteria Used to Diagnose Lupus?

Here are the 11 original ACR criteria, each explained in plain terms:

  1. Malar rash. A butterfly-shaped rash across the cheeks and nose. It spares the folds around the nose and mouth, which helps tell it apart from rosacea or eczema.
  2. Discoid rash. Raised, coin-shaped patches that can scar. These appear on the face, scalp, or other sun-exposed areas.
  3. Photosensitivity. Unusual skin reactions to sunlight, either a rash or a flare of other symptoms after sun exposure.
  4. Oral ulcers. Painless sores inside the mouth or nose, usually noticed by a doctor during examination rather than reported by the patient.
  5. Arthritis. Inflammation in two or more joints, causing pain, swelling, and tenderness. Unlike rheumatoid arthritis, lupus arthritis rarely causes permanent joint damage.
  6. Serositis. Inflammation of the lining around the lungs (pleuritis) or heart (pericarditis), causing chest pain that often worsens with breathing or lying flat.
  7. Renal disorder. Kidney involvement, detected by protein or red blood cell casts in the urine. Lupus nephritis is one of the more serious complications of the disease.
  8. Neurological disorder. Seizures or psychosis not explained by other causes, such as medication or metabolic problems.
  9. Hematologic disorder. Low red blood cells (hemolytic anemia), low white blood cells (leukopenia), or low platelets (thrombocytopenia).
  10. Immunologic disorder. Positive anti-double-stranded DNA (anti-dsDNA), anti-Smith (anti-Sm), or antiphospholipid antibodies. These are proteins the immune system makes against its own cells.
  11. Positive ANA. Antinuclear antibody test. ANA detects antibodies directed at the nucleus of cells. A positive result alone does not mean lupus, but a negative result makes lupus unlikely.

Do You Need All 11 Criteria to Be Diagnosed With Lupus?

No. The original rule required 4 of the 11 criteria, not all 11. And even that 4-out-of-11 rule was built for research studies, not clinical diagnosis.

In real practice, a rheumatologist can diagnose and treat lupus before a patient meets any formal threshold. Some patients have clear lupus based on kidney biopsy results and autoantibody patterns without ticking four boxes on the ACR list. Others meet four criteria but have a different condition entirely.

The criteria are a structured framework for consistency across research studies, not a gate that must be passed before treatment begins. What matters clinically is the overall picture: a pattern of multi-system inflammation, characteristic autoantibodies (especially ANA), and no better explanation for the findings.

What Is the Malar Rash Criterion for Lupus?

The malar rash is the butterfly-shaped rash that spreads across both cheeks and the bridge of the nose. It's flat or slightly raised, red or pink, and typically spares the nasolabial folds (the creases running from the nose to the corners of the mouth). That sparing pattern is what separates it from rosacea, which fills those folds.

The rash often appears or worsens after sun exposure. It can last days or weeks and may come and go with disease flares. In my experience reviewing lupus presentations, the malar rash is one of the most recognisable signs, but it's absent in a significant portion of lupus patients. Its absence doesn't rule out the diagnosis.

Under the newer EULAR/ACR 2019 criteria, the malar rash is grouped with other non-scarring skin findings and assigned a point value of 2, reflecting that it's meaningful but not definitive on its own.

How Are the Lupus Criteria Different From Lupus Symptoms?

This distinction causes a lot of confusion. And it matters.

lupus symptoms are what a patient experiences: fatigue, joint pain, hair loss, brain fog, chest pain, swelling. These are real and often debilitating. But many overlap with dozens of other conditions, from fibromyalgia to thyroid disease to other autoimmune disorders.

The classification criteria are a curated subset of findings, both symptoms and test results, that have been shown through research to distinguish lupus from those other conditions. They were selected because they're specific enough to be useful for research classification, not because they're the most common or most distressing features of the disease. autoimmune disorders

Fatigue, for example, affects over 90% of lupus patients and is often the most disabling symptom. It doesn't appear in any of the three major classification systems because it's too non-specific to help tell lupus apart from other conditions. Hair loss (alopecia) appears in the SLICC criteria but not the original ACR criteria. Fever appears in the EULAR/ACR 2019 criteria but not the earlier ones.

The practical takeaway: a patient can have severe, real lupus symptoms and not meet formal classification criteria. That doesn't mean their symptoms aren't being taken seriously. It means the criteria were never designed to capture every patient's experience.

What Blood Tests Are Included in the 11 Lupus Criteria?

Two of the 11 original ACR criteria are blood-test based:

  • Immunologic disorder. This covers three separate antibody findings: positive anti-dsDNA (antibodies against double-stranded DNA), positive anti-Sm (antibodies against a protein called Smith antigen), or positive antiphospholipid antibodies (which include anticardiolipin antibodies, lupus anticoagulant, and anti-beta-2 glycoprotein I).
  • Positive ANA. The antinuclear antibody test. This is the most sensitive test for lupus, meaning it's positive in over 95% of lupus patients. A negative ANA makes lupus very unlikely.

The hematologic criterion (criterion 9) also involves blood tests: a complete blood count showing low red cells, white cells, or platelets.

Under the newer EULAR/ACR 2019 criteria, the immunology domain expanded to include complement proteins (C3 and C4 levels, which drop during active lupus) and direct Coombs test (which detects antibodies on red blood cells). Anti-dsDNA and anti-Sm antibodies each carry higher point values than other findings, reflecting their stronger association with lupus specifically.

What I found when looking at how these tests are used clinically is that anti-dsDNA is particularly useful. Its levels tend to rise and fall with disease activity, making it helpful not just for diagnosis but for monitoring flares over time.

Have the 11 Criteria for Lupus Been Updated?

Yes. Twice. And the updates matter.

The 2012 SLICC Criteria

The Systemic Lupus International Collaborating Clinics group expanded the criteria to 17 items and reorganised them into clinical and immunological domains. The SLICC criteria were more sensitive than the original ACR criteria, catching 94% of actual lupus cases compared to 86%, while maintaining similar specificity.

They also allowed lupus nephritis confirmed by biopsy plus positive ANA or anti-dsDNA to qualify as lupus on its own, without needing to meet four separate criteria. The SLICC update added findings like non-scarring alopecia, synovitis (joint inflammation confirmed on examination), and low complement levels, which the original ACR criteria had missed.

The 2019 EULAR/ACR Criteria

The most current system, published jointly by the European League Against Rheumatism and the American College of Rheumatology, works differently from its predecessors. Instead of a simple count, it uses a weighted point system across ten domains:

  • Constitutional (fever): 2 points
  • Hematologic (low blood counts): 3 to 4 points depending on finding
  • Neuropsychiatric (seizures, psychosis, etc.): 2 to 3 points
  • Mucocutaneous (rashes, mouth sores, hair loss): 2 to 6 points
  • Serosal (pleuritis, pericarditis): 5 to 6 points
  • Musculoskeletal (joint involvement): 6 points
  • Renal (kidney involvement): 4 to 10 points
  • Antiphospholipid antibodies: 2 points
  • Complement proteins: 3 to 4 points
  • Lupus-specific antibodies (anti-dsDNA, anti-Sm): 6 points each

A positive ANA is required as an entry point. Without it, the scoring doesn't apply. A total score of 10 or more classifies the patient as having lupus.

This system was validated in 2,271 patients and showed better specificity than the SLICC criteria, meaning fewer false positives, while still catching real cases. The weighted approach reflects what clinicians already knew intuitively: lupus nephritis and anti-dsDNA positivity are stronger signals than joint pain or mouth sores alone.

Three Things Most Articles Get Wrong About Lupus Criteria

First, the criteria aren't a diagnostic checklist. They were built for research, to make sure clinical trials enrol the same type of patients across different centres. A rheumatologist diagnosing an individual patient uses clinical judgment, not a scoring sheet. Some patients get diagnosed and treated appropriately without ever meeting formal criteria.

Second, a positive ANA doesn't mean lupus. ANA is positive in roughly 5% of healthy people and in many other autoimmune conditions. Its value is in ruling lupus out when negative, not confirming it when positive. The EULAR/ACR 2019 criteria use ANA as a mandatory entry point precisely because a negative ANA makes lupus so unlikely. But a positive ANA alone means very little.

Third, meeting the criteria doesn't automatically mean treatment is needed. If a patient scores 10 points on the EULAR/ACR system but has mild, stable disease, the criteria classification doesn't dictate a treatment plan. Conversely, a patient with severe lupus nephritis may need aggressive treatment before they technically meet all formal criteria. The criteria inform the diagnosis. They don't drive the treatment decision.

Frequently Asked Questions

Can you have lupus without meeting the 11 criteria?

Yes. Doctors can diagnose and treat lupus based on clinical judgment even when formal criteria aren't fully met. The criteria were designed for research consistency, not as a diagnostic gate.

Which criterion is most important?

ANA is the most sensitive. It's positive in over 95% of lupus patients. Anti-dsDNA and anti-Sm are the most specific, meaning they're rarely positive in people who don't have lupus. Under the EULAR/ACR 2019 system, renal involvement and lupus-specific antibodies carry the highest point values.

Is the ANA test enough to diagnose lupus?

No. A positive ANA is a starting point, not a diagnosis. Many people with positive ANA don't have lupus. The full clinical picture, including symptoms, other blood tests, and organ involvement, is needed.

What is the difference between classification and diagnosis?

Classification criteria are used in research to define a consistent study population. Diagnosis is a clinical decision made by a doctor for an individual patient. The two overlap but aren't the same thing.

How long does it take to get a lupus diagnosis?

Research shows the average time from first symptoms to diagnosis is around six years, largely because lupus mimics many other conditions and symptoms often come and go. Early referral to a rheumatologist shortens this significantly.

Do the criteria cover all types of lupus?

The criteria cover systemic lupus erythematosus (SLE), the most common form. Cutaneous lupus (affecting mainly the skin), drug-induced lupus, and neonatal lupus have different presentations and aren't fully captured by these systems.

What to Do If You Suspect Lupus

If you have recurring joint pain, unexplained rashes, fatigue that doesn't improve with rest, or abnormal blood counts, ask your GP for an ANA blood test and a referral to a rheumatologist. Don't wait until you have four criteria checked off a list. That's not how diagnosis works in practice, and early assessment leads to better outcomes.

A rheumatologist will look at your full history, examine you, and order targeted tests based on what they find. The criteria are their reference framework, not yours to self-apply.

John Carter
About the author

John Carter

Undergraduate degree in mathematics/statistics from the University of Melbourne. PhD in Statistics from Harvard University

I'm a quantitative scientist with a deep passion for improving health outcomes through rigorous statistical methods and data-driven decision-making.

Connect on LinkedIn →

Sources

  1. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. (2012) "Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus" Arthritis and rheumatism. PMID: 22553077
  2. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. (2019) "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus" Annals of the rheumatic diseases. PMID: 31383717
  3. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) "Update οn the diagnosis and management of systemic lupus erythematosus" Annals of the rheumatic diseases. PMID: 33051219
  4. Aringer M, Petri M (2020) "New classification criteria for systemic lupus erythematosus" Current opinion in rheumatology. PMID: 32925250
  5. Aringer M, Johnson SR (2020) "Classifying and diagnosing systemic lupus erythematosus in the 21st century" Rheumatology (Oxford, England). PMID: 33280013